UBS keeps DKK 332 target for Novo Nordisk stock

Published on 10/16/2026 at 10:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 adjusted sales reached DKK 78.49 billion, up 7.00 percent at constant exchange rates. For Novo Nordisk stock, results arrive November 4, 2026.

Recent analyst view

UBS maintained a Hold rating and a DKK 332.00 price target on October 15, 2026.
Adjusted sales reached DKK 78.49 billion in the second quarter of 2026, up 7.00 percent at constant exchange rates.
Novo Nordisk stock traded at EUR 34.86 at 10:32 a.m. CEST at Lang & Schwarz on October 16, 2026.
The next financial-results announcement is scheduled for November 4, 2026.

Generischer Insulin-Pen auf weißem Tisch, klinische Beleuchtung, medizinisch — Novo Nordisk A/S (DK0062498333): generischer Insulin-Pen auf weißem Tisch in klinischer Beleuchtung, Illustration mit AI erstellt.

Novo Nordisk (ISIN DK0062498333) was trading at EUR 34.86 at Lang & Schwarz on October 16, 2026 at 10:32 a.m. CEST. On October 15, 2026, UBS maintained a Hold rating and a DKK 332.00 price target, according to Markets Insider.

Q2 sales and outlook

The latest reported quarter showed why Novo Nordisk remains a closely watched healthcare stock despite the cautious analyst stance. In the second quarter of 2026, adjusted sales reached DKK 78.49 billion, an increase of 7.00 percent at constant exchange rates. Adjusted operating profit was DKK 33.39 billion, up 11.00 percent at constant exchange rates, according to Globenewswire.

The same August 4, 2026 release showed a mixed forward picture. Novo Nordisk raised its full-year 2026 adjusted sales growth outlook from a range of minus 4.00 percent to minus 12.00 percent to a range of 0.00 percent to minus 6.00 percent at constant exchange rates. Adjusted operating profit growth received the same change, while the company attributed the improvement to higher expectations for GLP-1 product sales.

What matters before results?

The next hard data point is the third-quarter report. Novo Nordisk's investor calendar schedules the announcement for November 4, 2026, before the opening of Nasdaq Copenhagen, according to the company's investor calendar. That date will put the 2026 outlook beside fresh evidence on demand, pricing and the development of the GLP-1 portfolio.

For investors, the key comparison is between volume-led growth and the pressure visible in the guidance range. The second-quarter sales increase and operating-profit increase were both reported on an adjusted basis, excluding specified non-recurring effects. That distinction matters because the release also identified DKK 6.30 billion in non-cash impairment charges in the quarter.

November reporting date

The company has already held its Capital Markets Day on September 21, 2026, where management reviewed strategy, research and development, operations and performance. The next scheduled reporting date is November 4, 2026, when the first three quarters of 2026 will be announced.

Stock price during trading

Novo Nordisk's German-market indication stood at EUR 34.86 at Lang & Schwarz on October 16, 2026 at 10:32 a.m. CEST. The price is presented without a daily percentage because the dated Xetra closing reference could not be established from the eligible Xetra-specific sources used for this article.

The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.